METHYLERGONOVINE 0.2 MG TABLET
For 30 tablets
Pharmacies pay
$134.92 filed
30 × $4.49722 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$539.73 filed
30 × $17.99093 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
4.0× estimated
Medicare paid 4.0× what pharmacies pay.
Part D averages every strength and form sold under “Methylergonovine Maleate*” / “Methylergonovine Maleate” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$160.16 estimated
$134.92 + $20.24 (15%) + $5.00 fee per fill = $160.16
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
METHYLERGONOVINE 0.2 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “methylergonovine” and “methylergonovine maleate”, as its NDCs’ listings variously write the nonproprietary name.
FDA gives its dosage form as tablet and its route as oral.
FDA lists 6 labelers (the companies named on the label) for its NDCs, among them Teva Pharmaceuticals USA, Inc., Major Pharmaceuticals and Rising Pharma Holdings, Inc.
FDA’s Established Pharmacologic Class for it is Ergot Derivative.
The NADAC file of 2026-10-14 prices it under 13 NDCs (National Drug Codes); the FDA directory lists 10 of them.
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $134.92 for 30 tablets (30 × $4.49722 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The 6 labelers
| Labeler | NDCs | Pharmacies pay per unit |
|---|---|---|
| Amneal Pharmaceuticals NY LLC | 2 | $4.49722 per EA filed |
| Granules Pharmaceuticals Inc. | 2 | $4.49722 per EA filed |
| Rising Pharma Holdings, Inc. | 2 | $4.49722 per EA filed |
| Teva Pharmaceuticals USA, Inc. | 2 | $4.49722 per EA filed |
| American Health Packaging | 1 | $4.49722 per EA filed |
| Major Pharmaceuticals | 1 | $4.49722 per EA filed |
| Not listed as a package in the FDA directory | 3 | $4.49722 per EA filed |
All 13 NDCs, with labeler and price
- 00054-0639-05 · not listed as a package in the FDA directory · $4.49722 per EA · eff. 2026-09-23 filed
- 00054-0639-13 · not listed as a package in the FDA directory · $4.49722 per EA · eff. 2026-09-23 filed
- 00093-3655-22 · Teva Pharmaceuticals USA, Inc. · $4.49722 per EA · eff. 2026-09-23 filed
- 00093-3655-28 · Teva Pharmaceuticals USA, Inc. · $4.49722 per EA · eff. 2026-09-23 filed
- 00904-7282-10 · Major Pharmaceuticals · $4.49722 per EA · eff. 2026-09-23 filed
- 16571-0735-21 · Rising Pharma Holdings, Inc. · $4.49722 per EA · eff. 2026-09-23 filed
- 16571-0735-28 · Rising Pharma Holdings, Inc. · $4.49722 per EA · eff. 2026-09-23 filed
- 60687-0813-11 · not listed as a package in the FDA directory · $4.49722 per EA · eff. 2026-09-23 filed
- 60687-0813-94 · American Health Packaging · $4.49722 per EA · eff. 2026-09-23 filed
- 69238-1605-02 · Amneal Pharmaceuticals NY LLC · $4.49722 per EA · eff. 2026-09-23 filed
- 69238-1605-08 · Amneal Pharmaceuticals NY LLC · $4.49722 per EA · eff. 2026-09-23 filed
- 70010-0786-12 · Granules Pharmaceuticals Inc. · $4.49722 per EA · eff. 2026-09-23 filed
- 70010-0786-28 · Granules Pharmaceuticals Inc. · $4.49722 per EA · eff. 2026-09-23 filed
Compared with its class
The middle of its 13 NDCs’ NADAC prices is $4.49722 per EA filed.
Of the 4 other products in FDA’s Ergot Derivative class priced per EA, 1 has a higher middle NADAC price and 3 a lower one. The one in the middle is BROMOCRIPTINE 2.5 MG TABLET, at $1.60949 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $539.73 for 30 tablets, at an average of $17.99093 per EA in 2024 (2024-01-01 to 2024-12-31) for “Methylergonovine Maleate*” and “Methylergonovine Maleate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 191 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
11 of the product’s 13 NDCs have this Medicare figure; the other 2 do not, and the interactive card says why for each.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for METHYLERGONOVINE 0.2 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Methylergonovine Maleate* / Methylergonovine Maleate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name. *: CMS says this average reflects multiple routes of administration, which may have different unit prices. Only NADAC NDCs whose FDA route includes ORAL point at this name (11 of the 13 the name join matched); NDCs of another route or with no known FDA route do not. 1 of the 11 NDCs that point at this name is not listed in the FDA NDC Directory as a package of its own; its route was taken from FDA's record for the same product (labeler and product code).